NCT03445858 2026-02-18
Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults
Children's Hospital Medical Center, Cincinnati
Phase EARLY_PHASE1 Completed
Clinical Trials
10 trialsNCT03276832 2025-10-28
Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT04581382 2025-07-10
Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT03153410 2025-01-09
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase EARLY_PHASE1 Completed
NCT04188951 2024-12-04
HFHS-1801-A Pilot Study of Immunotherapy As Consolidation Therapy for Patients with Recurrent Head and Neck Cancer
Henry Ford Health System
Phase EARLY_PHASE1 Completed
NCT02981914 2024-04-22
Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation
University of Chicago
Phase EARLY_PHASE1 Completed
NCT02728830 2024-02-21
A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers
Duke University
Phase EARLY_PHASE1 Completed
NCT03395847 2023-11-18
Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Completed
NCT03599453 2023-07-18
Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer
Roswell Park Cancer Institute
Phase EARLY_PHASE1 Completed
NCT03197389 2021-05-19
Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer.
Universitaire Ziekenhuizen KU Leuven
Phase EARLY_PHASE1 Completed